- In January 2026, 10x Genomics and its partners, including Dana-Farber Cancer Institute, Brigham & Women’s Hospital, the Cancer Research Institute and CareDx, announced a series of collaborations to apply single-cell and spatial technologies across oncology, autoimmune disease, immuno-oncology and transplantation, alongside unaudited 2025 revenue of about US$642.8 million, or US$598.7 million excluding patent litigation settlements.
- These alliances, together with plans for a CLIA-certified lab and AI-enabled datasets, signal 10x Genomics’ intent to move its research platforms closer to regulated clinical and diagnostic workflows across multiple disease areas.
- Next, we’ll examine how 10x Genomics’ push into CLIA-lab infrastructure and clinical collaborations may reshape the company’s existing investment narrative.
We’ve found 12 US stocks that are forecast to pay a dividend…
